Wolfgang Weber

Active 1979–2025

303
Papers
44,311
Citations
113
h-index
271
i10-index

Citations

Citations per year for Wolfgang Weber1967: 1 citations1971: 1 citations1980: 1 citations1981: 4 citations1982: 3 citations1983: 2 citations1984: 17 citations1985: 45 citations1986: 34 citations1987: 31 citations1988: 35 citations1989: 15 citations1990: 24 citations1991: 24 citations1992: 29 citations1993: 23 citations1994: 32 citations1995: 28 citations1996: 25 citations1997: 20 citations1998: 26 citations1999: 46 citations2000: 61 citations2001: 93 citations2002: 117 citations2003: 148 citations2004: 196 citations2005: 256 citations2006: 303 citations2007: 367 citations2008: 422 citations2009: 435 citations2010: 312 citations2011: 370 citations2012: 326 citations2013: 258 citations2014: 275 citations2015: 244 citations2016: 248 citations2017: 301 citations2018: 273 citations2019: 1,049 citations2020: 1,189 citations2021: 1,358 citations2022: 1,147 citations2023: 786 citations2024: 1,309 citations2025: 597 citations2026: 27 citations1968–1970: no citations, so these years are not shown1972–1979: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,495 citing papers, 22.8% of this breakdownGermany: 1,801 citing papers, 11.8% of this breakdownChina: 1,163 citing papers, 7.6% of this breakdownItaly: 883 citing papers, 5.8% of this breakdownNetherlands: 834 citing papers, 5.5% of this breakdownUnited Kingdom: 812 citing papers, 5.3% of this breakdownFrance: 693 citing papers, 4.5% of this breakdownSwitzerland: 547 citing papers, 3.6% of this breakdownCanada: 409 citing papers, 2.7% of this breakdownJapan: 396 citing papers, 2.6% of this breakdownAustralia: 375 citing papers, 2.4% of this breakdownBelgium: 341 citing papers, 2.2% of this breakdown
0%22.8%Other 23.2%

Fields

  • Medicine74.5%
  • Biochemistry, Genetics and Molecular Biology13.8%
  • Materials Science2.1%
  • Engineering2%
  • Immunology and Microbiology1.7%
  • Computer Science1.5%
  • Other4.4%

Topics

  • Medical Imaging Techniques and Applications7.7%
  • Radiopharmaceutical Chemistry and Applications5.7%
  • Radiomics and Machine Learning in Medical Imaging4.5%
  • Prostate Cancer Treatment and Research4.1%
  • Neuroendocrine Tumor Research Advances2.4%
  • Prostate Cancer Diagnosis and Treatment2.2%
  • Other73.4%

Coauthors

All papers

Open in search
  1. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2014 cited by 3,292

  2. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2023 cited by 276

  3. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA

    Authors: , , , , , , , , , , , , , , , - European Urology 2020 cited by 267

  4. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT

    Authors: , , , , , , , , , , - Journal of Nuclear Medicine 2017 cited by 611

  5. Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04

    Authors: , , , , , , , , , , , , , - Journal of Nuclear Medicine 2019 cited by 246

  6. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer

    Authors: , , , , , , , , , , , , - European Urology 2018 cited by 308

  7. First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2019 cited by 262

  8. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Emmanuel Mitry, M. Nicolson, Juan Manuel O’Connor, Dermot O’Toole, Ulrich-Frank Pape, Marianne Pavel, John Ramage, Éric Raymond, Guido Rindi, Andrea Rockall, Philippe Ruszniewski, Ramón Salazar, Aldo Scarpa, Eva Sedláčková, Anders Sundin, Christos Toumpanakis, Marie‐Pierre Vullierme, Wolfgang Weber, Bertram Wiedenmann, Zeng Zheng-Pei - Annals of Oncology 2015 cited by 699

  9. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine

    Authors: , , - Journal of Nuclear Medicine 2019 cited by 270

  10. Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy

    Authors: , , , , , , , , - Journal of Nuclear Medicine 2019 cited by 238

  11. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2009 cited by 1,343

  12. Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy

    Authors: , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2018 cited by 332

  13. The Future of Nuclear Medicine, Molecular Imaging, and Theranostics

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2020 cited by 161

  14. Joint Imaging Platform for Federated Clinical Data Analytics

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Seifert, Ken Herrmann, Philipp Mayer, Hans‐Ulrich Kauczor, Tobias Penzkofer, Bernd Hamm, Winfried Brenner, Roman Kloeckner, Christoph Düber, Mathias Schreckenberger, Rickmer Braren, Georgios Kaissis, Marcus R. Makowski, Matthias Eiber, Andrei Gafita, Rupert Trager, Wolfgang Weber, Jakob Neubauer, Marco Reisert, Michael Bock, Fabian Bamberg, Jürgen Hennig, Philipp T. Meyer, Juri Ruf, Uwe Haberkorn, Stefan O. Schoenberg, Tristan Anselm Kuder, Peter Neher, Ralf Floca, Heinz‐Peter Schlemmer, Klaus Maier‐Hein - JCO Clinical Cancer Informatics 2020 cited by 71

  15. Long-Term Nephrotoxicity of177Lu-PSMA Radioligand Therapy

    Authors: , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2023 cited by 64

  16. The EANM practice guidelines for bone scintigraphy

    Authors: , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2016 cited by 444

  17. Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study

    Authors: , , , , , , , , , , - Journal of Nuclear Medicine 2014 cited by 263

  18. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , S. Eschmann, W. Dornoff, Birgit Siekmeyer, L Trampert, G. Gademann, Thomas Brunner, A Amthauer, Jens Ricke, Maciej Pech, Christian Rübe, Claudia Kirsch, S. Ezzidin, Heinz Schmidberger, M. Schreckenberger, M. Bamberg, Daniel Zips, Roland Bares, Christian la Fougère, Volker Budach, Winfried Brenner, Marcus Beck, R Freiherr von Gumppenberg, Daniel M. Aebersold, T Krause, H J Feldmann, A. Hertel, Georg Stüben, J. Sciuk, H Annweiler, G. Höll, W Oehler, I Schlöcker, R. Baum, B. Kimmig, Jürgen Dunst, E Henze, Ulf Lützen, Markus Schwaiger, Katharina Strehle, Winfried Alberti, Marc D. Piroth, Marco Tosch, Richard Pötter, Joachim Widder, Christian Herold, U Freund, Felix Momm, Wolfgang Weber, Marie‐Luise Sautter‐Bihl, Klaus Tatsch, Guido Hildebrandt, Bernd‐Joachim Krause - The Lancet Oncology 2020 cited by 177

  19. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0

    Authors: , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2022 cited by 105

  20. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria

    Authors: , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2022 cited by 100

  21. The added value of PSMA PET/MR radiomics for prostate cancer staging

    Authors: , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2021 cited by 83

  22. EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2 -Amplified Esophagogastric Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael F. Berger, Elisa de Stanchina, Barry S. Taylor, Jason S. Lewis, David B. Solit, Jorge A. Carrasquillo, Maurizio Scaltriti, Nikolaus Schultz, Yelena Y. Janjigian - Cancer Discovery 2018 cited by 147

  23. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo

    Authors: , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2015 cited by 304

  24. What Is Theranostics?

    Authors: , , , , , - Journal of Nuclear Medicine 2023 cited by 74